A United States bankruptcy judge has approved a settlement plan for Purdue Pharma, the maker of OxyContin, concluding thousands of lawsuits related to the opioid crisis. The decision ends the Sackler family's control over the company and bars them from selling opioids in the United States. The $7.4 billion settlement will direct funds to communities and individuals affected by opioid addiction, with the Sackler family contributing up to $7 billion and Purdue paying $900 million. Additionally, a separate fund will compensate victims, and Purdue will be restructured as a public benefit company focused on opioid use disorder treatments and overdose reversal medicines. The judge acknowledged the plan's limitations but emphasized its significance in addressing the opioid epidemic.